Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry Save Sight Registries Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry Read More »
Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry Save Sight Registries Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry Read More »
Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry Save Sight Registries Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry Read More »
The impact of disease activity on 5-year outcomes in patients undergoing treatment for neovascular age-related macular degeneration Save Sight Registries The impact of disease activity on 5-year outcomes in patients undergoing treatment for neovascular age-related macular degeneration Read More »
The Save Sight Keratoconus Registry – Optometry Module: an opportunity to use real-world data to advance eye care Save Sight Registries The Save Sight Keratoconus Registry – Optometry Module: an opportunity to use real-world data to advance eye care Read More »
Comparative Efficacy and Safety of Standard Versus Accelerated Corneal Crosslinking for Keratoconus: 1-Year Outcomes From the Save Sight Keratoconus Registry Study Save Sight Registries Comparative Efficacy and Safety of Standard Versus Accelerated Corneal Crosslinking for Keratoconus: 1-Year Outcomes From the Save Sight Keratoconus Registry Study Read More »
Efficient capture of high-quality real-world data on treatments for glaucoma: the Fight Glaucoma Blindness! Registry Save Sight Registries Efficient capture of high-quality real-world data on treatments for glaucoma: the Fight Glaucoma Blindness! Registry Read More »
Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis Save Sight Registries Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis Read More »
Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence Save Sight Registries Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence Read More »
Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands Save Sight Registries Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands Read More »
Neovascular age-related macular degeneration: A review of findings from the real-world Fight Retinal Blindness! registry Save Sight Registries Neovascular age-related macular degeneration: A review of findings from the real-world Fight Retinal Blindness! registry Read More »
Neovascular age-related macular degeneration at treatment intervals of 14 weeks or greater Save Sight Registries Neovascular age-related macular degeneration at treatment intervals of 14 weeks or greater Read More »
